Healio

FDA approves Caplyta as adjunctive therapy in adults with major depressive disorder

The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...
STAT

FDA approves J&J’s antipsychotic drug to treat depression

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...
Stocktwits on MSN

Johnson & Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder

The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...
BioPharma Dive

J&J brain drug acquired in $14.6B buyout cleared for broader use

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...
BioSpace

Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss

The mid-stage failure was unexpected to analysts at BMO Capital Markets, who viewed ‘770 as mostly derisked given its similar ...
PharmExec

FDA Approves Johnson and Johnson’s Caplyta

Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Johnson & Johnson posts strong Q3 2025 with robust sales, new acquisitions, and FDA approvals expanding oncology and CNS ...
The American Journal of Managed Care

FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...